Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
456.69
-4.13 (-0.90%)
At close: Mar 6, 2026, 4:00 PM EST
454.12
-2.57 (-0.56%)
After-hours: Mar 6, 2026, 7:52 PM EST
Vertex Pharmaceuticals Revenue
In the year 2025, Vertex Pharmaceuticals had annual revenue of $12.00B with 8.90% growth. Vertex Pharmaceuticals had revenue of $3.19B in the quarter ending December 31, 2025, with 9.55% growth.
Revenue (ttm)
$12.00B
Revenue Growth
+8.90%
P/S Ratio
9.67
Revenue / Employee
$1,875,203
Employees
6,400
Market Cap
116.01B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 12.00B | 981.20M | 8.90% |
| Dec 31, 2024 | 11.02B | 1.15B | 11.66% |
| Dec 31, 2023 | 9.87B | 938.50M | 10.51% |
| Dec 31, 2022 | 8.93B | 1.36B | 17.91% |
| Dec 31, 2021 | 7.57B | 1.37B | 22.06% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Regeneron Pharmaceuticals | 14.34B |
| BeOne Medicines AG | 5.34B |
| Incyte | 5.14B |
| argenx SE | 4.25B |
| Alnylam Pharmaceuticals | 3.71B |
| BioNTech SE | 3.70B |
| Royalty Pharma | 2.38B |
| Moderna | 1.94B |
VRTX News
- 1 day ago - Vertex to Participate in Upcoming March Investor Conferences - Business Wire
- 2 days ago - Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures - Business Wire
- 4 days ago - Vertex Pharmaceuticals Incorporated (VRTX) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha
- 7 days ago - 10 Best CEFs This Month: Average Yield Of 9.7% (February 2026) - Seeking Alpha
- 17 days ago - Vertex Pharmaceuticals Stock: Is The Bull Run Over (Rating Downgrade) - Seeking Alpha
- 17 days ago - Vertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3 - Business Wire
- 22 days ago - Vertex Pharmaceuticals Incorporated (VRTX) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 22 days ago - Vertex Pharma forecasts 2026 revenue in-line, expects growth in cystic fibrosis treatments - Reuters